Navigation Links
Genesis Pharmaceuticals Appoints KPMG to Help Develop a SOX 404 Compliance Program
Date:1/13/2009

LAIYANG, China, Jan. 13 /PRNewswire-Asia-FirstCall/ -- Genesis Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the "Company"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it engaged KPMG Huazhen ("KPMG"), a member firm of the KPMG network of independent member firms affiliated with KPMG International, to assist the Company in complying with the financial reporting and control requirements of Sarbanes-Oxley Act Section 404 ("SOX 404").

KPMG will work closely with Genesis' management to help prepare a SOX 404 compliance program by sharing with Genesis' management its knowledge about how other firms comply with SOX 404 requirements on an ongoing basis. As part of compliance with SOX 404, Genesis and its external auditor will examine and report on the adequacy of the Company's internal financial reporting and control systems after documenting and testing financial reporting and control procedures. Genesis' SOX 404 compliance program will address how management's decision making is linked to financial reporting risks.

"We are pleased to engage KPMG for this important undertaking, part of our efforts to ensure that Genesis is in full compliance with the requirements of SOX 404," said Mr. Wubo Cao, Chief Executive Officer of Genesis. "We hope that our efforts increase shareholders' confidence in our financial reporting standards and commitment to upgrade to a senior stock exchange."

About Genesis Pharmaceuticals Enterprises, Inc.

Genesis Pharmaceuticals Enterprises, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Northeast China in an Economic Development Zone in Laiyang City, Shandong province. Genesis is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, and granule form.

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's implementation of SOX 404. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

     Genesis Pharmaceuticals Enterprises, Inc.
     Ms. Elsa Sung, CFO
     Phone:   +1-954-727-8435
     Email:   elsasung@jiangbo.com
     Website:http://www.genesispharmaceuticals.com


     CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone:    +1-646-213-1915
     Email:    crocker.coulson@ccgir.com
     Web site:http://www.ccgirasia.com

'/>"/>
SOURCE Genesis Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. OmegaGenesis Announces Angiogenesis Application Collaboration
2. Cardiogenesis Announces Addition of Raymond W. Cohen to Board of Directors
3. Tissue Genesis Applies CE Mark to Its Adult Stem Cell Isolation System
4. Cardiogenesis Reports Third Quarter 2008 Results
5. ThermoGenesis Presentation at Rodman & Renshaw Conference
6. Genesis Pharmaceuticals Launches New Corporate Website
7. ThermoGenesis Corp. to Announce First Quarter Fiscal 2009 Results on November 6, 2008
8. ThermoGenesis Announces Distribution Agreement for Bone Marrow Stem Cell Device
9. ThermoGenesis Reports Record Quarterly Revenues of $7.2 Million; Full Year Revenues Increase 31 Percent
10. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol
11. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2008 on September 9, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017 The Global Microfluidic Chips ... is a specialized and comprehensive study on the existing state of ... , Europe and Asia-Pacific ... East and Africa . ... Browse 172 Tables and Figures, ...
(Date:3/28/2017)... California (PRWEB) , ... March 28, 2017 , ... ... its flagship product, AllegroGraph , has been named a ‘Champion’ by Bloor Research ... is the highest ranked product in its class, and, thanks to Gruff, it was ...
(Date:3/28/2017)... 2017 Summary This report provides ... and its partnering interests and activities since 2010. Description ... in-depth insight into the partnering activity of one of the ... reports are prepared upon purchase to ensure inclusion of the ... The report will be delivered in PDF format within 1 ...
(Date:3/28/2017)... 2017  Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a ... therapies for metabolic and endocrine disorders, today announced that ... will deliver a corporate presentation at H.C. Wainwright & ... held April 3, 2017 at the St. Regis Hotel ... presentation are as follows: H.C. ...
Breaking Biology Technology:
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... Matching enables to match face pictures against each other or against large databases. ... Systems) ... the fastest software for biometric Face Matching on the market. The speed is ...
(Date:3/7/2017)... , March 7, 2017   HireVue , the ... global companies identify the best talent, faster, today announced ... Sales Officer (CSO) and Diana Kucer as ... out a seasoned executive team poised to drive continued growth ... on a year of record bookings in 2017. ...
(Date:3/2/2017)... 2017 Who risk to be deprived of ... full report: https://www.reportbuyer.com/product/4313699/ WILL APPLE AND ... Fingerprint sensors using capacitive technology represent a fast ... Idex forecasts an increase of 360% of the number ... the fingerprint sensor market between 2014 and 2017 (source ...
Breaking Biology News(10 mins):